Long-term Morbidity of Testicular Cancer Treatment

Urologic Clinics of North America

Volumn 42, Issue 3, 2015, Pages 393-408

  Fung, Chunkit ^a   Fossa, Sophie D ^b   Williams, Annalynn ^c   Travis, Lois B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cardiovascular disease; Hypogonadism; Long term morbidity; Nephrotoxicity; Neurotoxicity; Second malignant neoplasms; Survivorship; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

AVASCULAR NECROSIS; BLADDER CANCER; CANCER RISK; CANCER SURGERY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COLON CANCER; ESOPHAGUS CANCER; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; HYPOGONADISM; KIDNEY CANCER; LEUKEMIA; LIFESTYLE MODIFICATION; LUNG CANCER; LUNG TOXICITY; MELANOMA; MORBIDITY; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PANCREAS CANCER; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLEURA CANCER; PNEUMONIA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RECTUM CANCER; REVIEW; SECOND CANCER; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; TINNITUS; CHEMICALLY INDUCED; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KIDNEY DISEASE; LIFESTYLE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; NEUROLOGIC DISEASE; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVOR; TESTICULAR NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPOGONADISM; KIDNEY DISEASES; LIFE STYLE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 84938294320     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.05.002     Document Type: Review

References (100)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Einhorn L.H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87(3):293-298.
3. Hanna N., Einhorn L.H. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol 2014, 32(28):3085-3092.
4. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8(9):784-796.
5. Nigam M., Aschebrook-Kilfoy B., Shikanov S., et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015, 33(5):623-631.
6. Hanna N.H., Einhorn L.H. Testicular cancer-discoveries and updates. N Engl J Med 2014, 371(21):2005-2016.
7. Einhorn L.H. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981, 41(9 Pt 1):3275-3280.
8. Travis L.B., Ng A.K., Allan J.M., et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 2012, 104(5):357-370.
9. Haugnes H.S., Bosl G.J., Boer H., et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012, 30(30):3752-3763.
10. Aziz N.M. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol 2007, 46(4):417-432.
11. Travis L.B., Rabkin C.S., Brown L.M., et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006, 98(1):15-25.
12. Wood M.E., Vogel V., Ng A., et al. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012, 30(30):3734-3745.
13. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97(18):1354-1365.
14. Travis L.B., Andersson M., Gospodarowicz M., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000, 92(14):1165-1171.
15. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993, 11(4):598-606.
16. Kollmannsberger C., Beyer J., Droz J.P., et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998, 16(10):3386-3391.
17. Kollmannsberger C., Hartmann J.T., Kanz L., et al. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999, 83(6):860-863.
18. Travis L.B., Curtis R.E., Storm H., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997, 89(19):1429-1439.
19. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007, 25(28):4370-4378.
20. van den Belt-Dusebout A.W., Aleman B.M., Besseling G., et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009, 75(5):1420-1429.
21. Bachaud J.M., Berthier F., Soulie M., et al. Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol 1999, 50(2):191-197.
22. Hauptmann M., Fossa S.D., Stovall M., et al. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2015, 112(1):44-51.
23. Classen J., Schmidberger H., Meisner C., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003, 21(6):1101-1106.
24. Jones W.G., Fossa S.D., Mead G.M., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005, 23(6):1200-1208.
25. Fung C., Fossa S.D., Milano M.T., et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2013, 31(30):3807-3814.
26. Feldman D.R., Schaffer W.L., Steingart R.M. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 2012, 10(4):537-544.
27. Haugnes H.S., Wethal T., Aass N., et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010, 28(30):4649-4657.
28. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21(8):1513-1523.
29. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18(8):1725-1732.
30. van den Belt-Dusebout A.W., Nuver J., de Wit R., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006, 24(3):467-475.
31. Goff D.C., Lloyd-Jones D.M., Bennett G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl 2):S49-S73.
32. Nuver J., De Haas E.C., Van Zweeden M., et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010, 23(1):247-253.
33. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120(2):617-624.
34. Dearnaley D.P., Horwich A., A'Hern R., et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 1991, 27(6):684-691.
35. Nuver J., Lutke Holzik M.F., van Zweeden M., et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 2005, 15(6):399-405.
36. O'Sullivan J.M., Huddart R.A., Norman A.R., et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003, 14(1):91-96.
37. Van Barneveld P.W., van der Mark T.W., Sleijfer D.T., et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 1984, 130(6):1078-1081.
38. Haugnes H.S., Aass N., Fossa S.D., et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009, 27(17):2779-2786.
39. Fossa S.D., Gilbert E., Dores G.M., et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007, 99(7):533-544.
40. Donat S.M. Peri-operative care in patients treated for testicular cancer. Semin Surg Oncol 1999, 17(4):282-288.
41. Vickers A.E., Rose K., Fisher R., et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 2004, 32(5):577-590.
42. Tanaka H., Ishikawa E., Teshima S., et al. Histopathological study of human cisplatin nephropathy. Toxicol Pathol 1986, 14(2):247-257.
43. Hansen S.W., Groth S., Daugaard G., et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988, 6(11):1728-1731.
44. Fossa S.D., Aass N., Winderen M., et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002, 13(2):222-228.
45. Nuver J., Smit A.J., Sleijfer D.T., et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004, 40(5):701-706.
46. Bosl G.J., Leitner S.P., Atlas S.A., et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986, 4(11):1684-1689.
47. Peacock J.M., Ohira T., Post W., et al. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2010, 160(3):464-470.
48. Astor B.C., Hallan S.I., Miller E.R., et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008, 167(10):1226-1234.
49. Hartmann J.T., Kollmannsberger C., Kanz L., et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999, 83(6):866-869.
50. Travis L.B., Fossa S.D., Sesso H.D., et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014, 106(5). [pii:dju044].
51. de Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001, 19(6):1629-1640.
52. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316(23):1435-1440.
53. Brydoy M., Oldenburg J., Klepp O., et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009, 101(24):1682-1695.
54. Glendenning J.L., Barbachano Y., Norman A.R., et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010, 116(10):2322-2331.
55. Sprauten M., Darrah T.H., Peterson D.R., et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012, 30(3):300-307.
56. Oldenburg J., Kraggerud S.M., Brydoy M., et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007, 5:70.
57. Hershman D.L., Lacchetti C., Dworkin R.H., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014, 32(18):1941-1967.
58. Bokemeyer C., Berger C.C., Hartmann J.T., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998, 77(8):1355-1362.
59. Rybak L.P. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007, 15(5):364-369.
60. Oldenburg J., Kraggerud S.M., Cvancarova M., et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007, 25(6):708-714.
61. Ross C.J., Katzov-Eckert H., Dube M.P., et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009, 41(12):1345-1349.
62. Yang J.J., Lim J.Y., Huang J., et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013, 94(2):252-259.
63. Pussegoda K., Ross C.J., Visscher H., et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013, 94(2):243-251.
64. Xu H., Robinson G.W., Huang J., et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 2015, 47(3):263-266.
65. Janelsins M.C., Kesler S.R., Ahles T.A., et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014, 26(1):102-113.
66. Fossa S.D., de Wit R., Roberts J.T., et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003, 21(6):1107-1118.
67. Schagen S.B., Boogerd W., Muller M.J., et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008, 47(1):63-70.
68. Skoogh J., Steineck G., Stierner U., et al. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment. Acta Oncol 2012, 51(2):185-197.
69. Pedersen A.D., Rossen P., Mehlsen M.Y., et al. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009, 15(2):296-301.
70. Skaali T., Fossa S.D., Andersson S., et al. A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 2011, 22(5):1062-1070.
71. Wefel J.S., Vidrine D.J., Marani S.K., et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 2014, 23(6):626-633.
72. Skaali T., Fossa S.D., Andersson S., et al. Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 2011, 70(5):403-410.
73. Skakkebaek N.E., Rajpert-De Meyts E., Main K.M. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001, 16(5):972-978.
74. Sprauten M., Brydoy M., Haugnes H.S., et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol 2014, 32(6):571-578.
75. Huddart R.A., Norman A., Moynihan C., et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005, 93(2):200-207.
76. Wiechno P., Demkow T., Kubiak K., et al. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol 2007, 52(5):1448-1454.
77. Gerl A., Muhlbayer D., Hansmann G., et al. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001, 91(7):1297-1303.
78. Eberhard J., Stahl O., Cohn-Cedermark G., et al. Sexual function in men treated for testicular cancer. J Sex Med 2009, 6(7):1979-1989.
79. Brydoy M., Fossa S.D., Klepp O., et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005, 97(21):1580-1588.
80. Dahl A.A., Bremnes R., Dahl O., et al. Is the sexual function compromised in long-term testicular cancer survivors?. Eur Urol 2007, 52(5):1438-1447.
81. Hintikka J., Niskanen L., Koivumaa-Honkanen H., et al. Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 2009, 6(7):2049-2057.
82. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95(6):2536-2559.
83. Ondrusova M., Ondrus D., Dusek L., et al. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 2009, 56(6):473-479.
84. Rochira V., Balestrieri A., Madeo B., et al. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur J Endocrinol 2006, 154(2):175-185.
85. Haugnes H.S., Aass N., Fossa S.D., et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007, 18(2):241-248.
86. Nuver J., Smit A.J., Wolffenbuttel B.H., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005, 23(16):3718-3725.
87. Winquist E.W., Bauman G.S., Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 2001, 24(6):603-606.
88. Cook A.M., Dzik-Jurasz A.S., Padhani A.R., et al. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br J Cancer 2001, 85(11):1624-1626.
89. Kaila R., Wolman R.L. Groin pain in athletes: a consequence of femoral head avascular necrosis after testicular cancer chemotherapy. Clin J Sport Med 2006, 16(2):175-176.
90. van den Berkmortel F., de Wit R., de Rooy J., et al. Osteonecrosis in patients with testicular tumours treated with chemotherapy. Neth J Med 2004, 62(1):23-27.
91. Reilley M.J., Jacobs L.A., Vaughn D.J., et al. Health behaviors among testicular cancer survivors. J Community Support Oncol 2014, 12(4):121-128.
92. Shinn E.H., Swartz R.J., Thornton B.B., et al. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol 2010, 28(13):2274-2279.
93. Demark-Wahnefried W., Aziz N.M., Rowland J.H., et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005, 23(24):5814-5830.
94. Institute of Medicine. From cancer patient to cancer survivor: lost in transition. 2005, National Academies Press, Washington, DC. M. Hewitt, S. Greenfield, E. Stovall (Eds.).
95. Boer H., Nuver J., Lefrandt J.D., et al. Easy navigating through the forest of survivorship care. J Clin Oncol 2014, 32(1):61-62.
96. Bajorin D.F. The graying of testis cancer patients: what have we learned?. J Clin Oncol 2007, 25(28):4341-4343.
97. Travis L.B., Beard C., Allan J.M., et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010, 102(15):1114-1130.
98. Wanderas E.H., Fossa S.D., Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997, 33(2):253-262.
99. Richiardi L., Scelo G., Boffetta P., et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007, 120(3):623-631.
100. Hemminki K., Liu H., Sundquist J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol 2010, 21(7):1546-1551.